Latest News and Press Releases

Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis...

600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study...

Data published in Obesity journal show enhanced weight loss effect of NT-0796 when combined with semaglutide in preclinical obesity modelObese state completely reversed with 30% weight loss and...

Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025. COO Valerie Ceva will...

Austin, TX, USA, March 10, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Venous Stents Market Size, Trends and Insights By Technology (Iliac Vein Stent...

Inflammasome inhibition in obese animal model with heart failure was cardioprotective & improved metabolic parameters.

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

BURNABY, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation...

Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic IL-18 driven Hyperinflammatory Syndrome in patients...